Antitumor Activity of &lt;i&gt;Diospyros peregrina&lt;/i&gt; on Ehrlich Ascites Carcinoma in Mice

Raju, A; Y, Venu Gopal; Ravindranath, A.; Gohain, Kalpana; Reddy, P Praveen

doi:10.3329/jsr.v3i2.6787

Cited by 10 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of their biocompatibility, NEs have been widely used in the medical field for delivery and controlled release of the hydrophobic anticancer drugs because they present a very large surface area and good long-term stability. As expected in the EAC control group, a significant increase in body weight was observed [10]. However, animals treated with DOX-Sol showed a further significant decrease in the body weight indicating more reduction in the i.p.…”

Section: Discussionsupporting

confidence: 79%

See 1 more Smart Citation

Antitumor activity of doxorubicine-loaded nanoemulsion against Ehrlich ascites carcinoma-bearing mice

Alkhatib¹,

Alkreathy²,

Balamash³

et al. 2016

Trop. J. Pharm Res

View full text Add to dashboard Cite

Purpose: To evaluate the antitumor activity of doxorubicine (DOX)-loaded nanoemulsion (NE) on Ehrlich ascites carcinoma (EAC)-bearing Swiss albino mice. Methods: The mice were divided into five groups (n = 20) according to the administered drug. Groups I -V were labeled as negative control (normal), positive control of the untreated EAC bearing mice (EAC control), blank nanoemulsion (BI-NE), DOX-loaded-NE (DOX/LNE) and free DOX (DOX-Sol), respectively. Cardiotoxicity was assessed by measuring changes in body and organ weight, analyzing serum enzymes and lipids, and examining histological changes in heart tissues by light microscopy. In addition, mean survival time (MST), increase in life span (ILS) and survival (S) of the mice were determined.Results: DOX/LNE group reduced levels of serum enzymes and lowered damage to heart tissues relative to DOX-Sol group. The MST of the DOX/LNE group (80 ± 0.0 days) was significantly greater than that for

show abstract

Section: Discussionsupporting

confidence: 79%

“…The MST, % ILS and % S of each group containing ten mice were monitored by recording the daily mortality for 80 days. ILS were calculated using Eq 1 [10].…”

Section: Survival Studymentioning

confidence: 99%

Antitumor activity of doxorubicine-loaded nanoemulsion against Ehrlich ascites carcinoma-bearing mice

Alkhatib¹,

Alkreathy²,

Balamash³

et al. 2016

Trop. J. Pharm Res

View full text Add to dashboard Cite

show abstract

“…Daily monitoring and recording of the mortality were done for 60 days to assess the mean survival time (MST), increased life span percentage (% ILS) and survival percentage (% S). The MST, % ILS and % S were calculated based on the following equations 27 .…”

Section: Survival Studymentioning

confidence: 99%

Doxorubicin supplemented with pravastatin in lipid nanoemulsion induces antineoplastic activity with limited hepatotoxicity and cardiotoxicity in tumor-bearing mice

Alkhatib

Alkreathy

Omar

et al. 2021

Asian Journal of Pharmaceutical Research and Health Care

View full text Add to dashboard Cite

Doxorubicin (DXR) is widely indicated as anticancer drug, but serious cardiotoxicity limits its clinical application. Recently, Pravastatin (PS) is one of the statins that appear to possess a potential role in cancer therapy despite its hepatotoxicity. Interestingly, drug delivery systems are designed for targeted and controlled delivery of one or more drugs loaded in nanoparticles, holding an enormous potential in therapeutics. Therefore, the aim of the current study was to assess the tolerability of a novel nanoemulsion formulation holding DXR and pravastatin (DXR+PS/LNE) in Swiss albino mice bearing Ehrlich Ascites Carcinoma (EAC). The efficacy and tolerability of nanoemulsion formulation was assessed by monitoring body weight changes, biochemical and histopathological profiles of cardiac and hepatic tissues. The formulated DXR+PS/ LNE has mean droplet diameter of 139.90±3.85 nm. The present findings indicated that DXR+PS/LNE caused a significant decrease in body weight change and a 217.35 % increase in the mean survival time compared to EAC-challenged mice. In addition, no significant changes in biochemical parameters were detected compared to corresponding controls. The current preclinical results suggest that the nanoemulsion formulation of doxorubicin with pravastatin could be a promising novel cancer therapy, in terms of tolerability.

show abstract

“…The EAC control group has significantly increased in body weight than the other groups, which is attributed to the growth of the EAC in the peritoneal cavity. [ 12 ] By comparing the results of our experimental groups and previous studies, treatment with the DOX/LNE and DOX+GEM/LNE (0.1 and 0.2mL) prevented the body weight from the great loss induced by DOX and huge increase that happened in the EAC control group. [ 9 17 18 ] Furthermore, the MST of the tumor-bearing mice treated with GEM/LNE, DOX/LNE, GEM+DOX-Sol, GEM+DOX/LNE (0.1mL), and GEM+DOX/LNE (0.2mL) formulations exceeded the MSTs of Bl-NE, GEM-Sol, and DOX-Sol treatment, which implies an enhancement in the efficacy of the antitumor drugs.…”

Section: Discussionmentioning

confidence: 91%

“…[ 11 ] The other 10 mice of each group were left to determine the mean survival time (MST) as described elsewhere. [ 12 ]…”

Section: S Ubjects and M Ethodsmentioning

confidence: 99%

In vivo evaluation of the anticancer activity of the gemcitabine and doxorubicin combined in a nanoemulsion

2018

View full text Add to dashboard Cite

Context:Doxorubicin (DOX) and gemcitabine (GEM) are anticancer drugs that were combined in a nanoemulsion (NE) to reduce their adverse side effects.Aim:To detect the antitumor activity of the combination formulas of GEM and DOX, loaded either in water (GEM+DOX-Sol) or in NEs (GEM–DOX combination/loaded NE [GEM+DOX/LNE]), in female Swiss albino mice inoculated with Ehrlich ascites carcinoma (EAC).Settings and Design:The anticancer assessment of the NE formulas was implemented in 200 mice, which were divided into 10 groups.Materials and Methods:It includes the detection of the change in body weight, analysis of the hematological and serum biochemical profiles, and study of the histopathologic alterations of the heart tissues.Statistical Analysis:One-factor analysis of variance was used.Results:Mice treated with GEM + DOX/LNE, which have an z-average of 155.38±2.33nm and zeta potential of −38.5±1.3 mV, recorded a considerable improvement in the mean survival time (MST), which was 60 days, as compared to the EAC control group, which has an MST of 28 days. It also restored the hematological and serum biochemical parameters toward normal values.Conclusions:The combination of GEM and DOX in NE has significantly diminished the cardiotoxicity of DOX and hematotoxicity of GEM while improving their antitumor properties.

show abstract

Antitumor Activity of <i>Diospyros peregrina</i> on Ehrlich Ascites Carcinoma in Mice

Cited by 10 publications

References 14 publications

Antitumor activity of doxorubicine-loaded nanoemulsion against Ehrlich ascites carcinoma-bearing mice

Antitumor activity of doxorubicine-loaded nanoemulsion against Ehrlich ascites carcinoma-bearing mice

Doxorubicin supplemented with pravastatin in lipid nanoemulsion induces antineoplastic activity with limited hepatotoxicity and cardiotoxicity in tumor-bearing mice

In vivo evaluation of the anticancer activity of the gemcitabine and doxorubicin combined in a nanoemulsion

Contact Info

Product

Resources

About